secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001193125-24-191500
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront
--------------------------------------------------------------------------------

- Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.
- Eligible for up to $323M in development/regulatory milestones and up to $1.488B in commercial sales milestones.
- License covers SAR446309, SAR446329, and SAR446368 (AMX-525) masked T-cell engagers and protease-cleavable masking platform.
- Exclusive worldwide license for oncology and infectious disease, excluding ophthalmology; low single-digit to low double-digit tiered royalties.
- Closing contingent on expiration or termination of applicable HSR waiting period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524191500/0001193125-24-191500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524191500/d880653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-191500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer